MARKET COMPOSITE
BIMI - BOQI International Medical Inc8:00:00 PM 3/28/2024
Price
$1.68
-0.14 (-7.64%)
BOQI International Medical Inc. engages in the retail and wholesale distribution of pharmaceutical and other healthcare products in the People's Republic of China. The company offers Chinese and western medicines, Chinese herbal medicines, healthcare devices, health foods, other food items, personal care products, and daily necessities under the Boqi Pharmacy brand name; and prescription drugs, OTC drugs, nutritional supplements, and sundry products. It operates through a network of sixteen directly owned stores. The company was formerly known as NF Energy Saving Corporation and changed its name to BOQI International Medical Inc. in December 2019. BOQI International Medical Inc. was incorporated in 2000 and is based in Dalian, the People's Republic of China.
Stock Chart

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

Stock news

    New York, Jan. 03, 2024 (GLOBE NEWSWIRE) -- BIMI Holdings Inc. (NASDAQ: BIMI) (“BIMI” or the “Company”), previously known as (BIMI International Medical Inc.) a healthcare products and services provider, today announced the results of the Company’s 2022 Annual General Meeting of Stockholders (the “Annual Meeting”) held on Dec 29, 2023 at 11:00 a.m. at the offices of the Company, 725 5th Ave, New York, NY 10022. At the Annual General Meeting the shareholders voted and approved; 1. The election of

    NEW YORK, Dec. 19, 2023 (GLOBE NEWSWIRE) -- BIMI International Medical Inc. (the “Company”), a leading medical solutions provider, today announced its financial results for the three months and nine months ended September 30, 2023. Revenues for the three months ended September 30, 2023 and 2022 were $2,523,193 and $4,932,479, respectively. Revenues for the nine months ended September 30, 2023 and 2022 were $11,278,496 and $10,476,224, respectively. The revenues of the Zhongshan, Qiangsheng, Eura

    BIMI Announces Buyback of Warrants11-28-2023 13:00:00 PM

    NEW YORK, NY, Nov. 28, 2023 (GLOBE NEWSWIRE) -- BIMI International Medical Inc. (NASDAQ: BIMI, "BIMI"), a healthcare products and services provider, today announced its entry into material definitive agreements with certain of its warrant holders, pursuant to which BIMI agreed to buy back an aggregate of 7,066,913 warrants to purchase shares of common stock of the Company from these warrant holders. BIMI agreed to pay $0.30 for each share of common stock underlying the warrant, or an aggregate p

    NEW YORK, Nov. 27, 2023 (GLOBE NEWSWIRE) -- BIMI International Medical Inc. (the “Company”) today announced that on November 21, 2023, the Company received a notification letter from The Nasdaq Stock Market LLC (“Nasdaq”) stating that, because the Company has not yet filed its Quarterly Report on Form 10-Q for the period ended September 30, 2023 (the “Third Quarter Form 10-Q”), the Company is no longer in compliance with Nasdaq Listing Rule 5250(c)(1). Nasdaq Listing Rule 5250(c)(1) requires lis

    NEW YORK, Nov. 27, 2023 (GLOBE NEWSWIRE) -- BIMI International Medical Inc. (the “Company”), a leading medical solutions provider, today announced its financial results for the three months ended June 30, 2023. The Company reported a significant increase in gross margin underlining the ongoing success of its business strategy and operational effectiveness. Revenues for the six months ended June 30, 2023 and 2022 were $8,755,303 and $5,543,745, respectively. Compared with the same period in 2022,

    NEW YORK, NY, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Phenix Bio Inc., a wholly owned subsidiary of BIMI International Medical Inc. (NASDAQ: BIMI), a leading global healthcare provider, announces the official launch of its "CUCA 3.0 Product Line through China Duty Free Group's (CDFG) online mini program sales platform. This significant milestone means China Duty Free’s 26 million members can now purchase Phenix’s products directly from CDFG, solidifying the previous purchase agreement between Phenix a

    NEW YORK, NY, Oct. 30, 2023 (GLOBE NEWSWIRE) -- BIMI International Medical Inc. (NASDAQ: BIMI, “BIMI”), a healthcare products and services provider today announced that its subsidiary, Phenix Bio Inc., appointed Hao Mu Pte. Ltd., a Singapore company (“Hao Mu”), as its exclusive distributor responsible for the distribution of Phenix’s 17 herbal supplements in Hong Kong, Taiwan and Macau. Pursuant to the terms of a sales agreement entered into on October 29, 2023, Hao Mu must make annual purchases

    NEW YORK, NY, Oct. 30, 2023 (GLOBE NEWSWIRE) -- BIMI International Medical Inc. (NASDAQ: BIMI, “BIMI”), a healthcare products and services provider today announced that its subsidiary, Phenix Bio Inc., appointed Hao Mu Pte. Ltd., a Singapore company (“Hao Mu”), as a distributor responsible for the distribution of Phenix’s 17 herbal supplements in Mainland China. Pursuant to the terms of a sales agreement entered into on October 29, 2023, Hao Mu must make annual purchases of at least $5 million i

    NEW YORK, NY, Sept. 22, 2023 (GLOBE NEWSWIRE) -- BIMI International Medical Inc. (NASDAQ: BIMI, "BIMI"), a healthcare products and services provider today announced its subsidiary, Phenix Bio Inc., appointed Hao Mu Pte. Ltd., a Singapore company, as its exclusive distributor responsible for the distribution of Phenix's 17 herbal supplements throughout the Association of Southeast Asian Nations (ASEAN) 10 member countries. Pursuant to the terms of a sales agreement entered on September 20, 2023,

    NEW YORK, NY, Aug. 07, 2023 (GLOBE NEWSWIRE) -- BIMI International Medical Inc. (NASDAQ: BIMI, “BIMI”), a leading global provider of healthcare services and innovative medical solutions, today announced the formation of a strategic partnership between its subsidiary, Phenix Bio Inc. (“Phenix”) and China Duty Free Group (“CDFG”), one of the largest and most influential state-owned duty-free retail enterprises in China. The Purchase Agreement between Phenix and CDFG, which became effective on Augu